当日关注点 来自交易信息汇总：2月26日主力资金净流出2570.18万元，散户资金净流入1964.72万元。 截至2026年2月26日收盘，爱尔眼科(300015)报收于10.59元，下跌1.03%，换手率0.56%，成交量44.33万 手，成交额4.7亿元。 董秘最新回复 投资者： 新春伊始，相关部门将继续加大力度扩消费，持续挖掘投资新消费市场，作为医疗消费的龙 头公司，如何提升核心竞争力，深化管理水平，改善各地区医院末梢治理效能，大力实施科技赋能医疗 服务，切实提升消费医疗的整体服务质量，加大宣传自身眼科医疗优势，在新一轮消费刺激赢得先机， 用先进的医疗水平让消费者放心、患者满意、家人安心？ 董秘： 谢谢您对公司的关注。公司以患者为中心，持续提升医疗技术、创新服务模式，满足患者的多 层次需求，让患者满意、家人安心、社会尊重，从而不断提高品牌影响力，实现高质量的可持续成长。 投资者： 请问，公司去年年末没有发布业绩预告，近期会发布业绩快报吗。 董秘： 谢谢您对公司的关注。根据《深圳证券交易所创业板股票上市规则（2024 年修订）》6.2.2款规 定，公司无需发布业绩预告。2025年度经营正常，将于2026年 ...

Core Viewpoint - Guangzheng Eye Hospital Group announced that its controlling shareholder, Guangzheng Investment, has had 9.15 million shares frozen due to a judicial order, which represents 7.08% of its holdings and 1.78% of the company's total share capital. The freeze is effective from January 30, 2026, to January 29, 2029, and will not affect the company's control or operations significantly [1][2]. Group 1 - Guangzheng Investment's frozen shares amount to 9.15 million, accounting for 7.08% of its total holdings and 1.78% of the company's total share capital [1][2]. - The judicial freeze was initiated by the Dongguan Intermediate People's Court in Guangdong Province [2]. - The company stated that this share freeze will not lead to any change in control and that it maintains independence in assets, business, and finance [2]. Group 2 - Guangzheng Eye Hospital has reported negative net profits for 12 consecutive years from 2013 to 2024, with a projected revenue of 893 million yuan in 2024, a decline of 16.94% year-on-year [3]. - The company expects a net loss of 3 to 5 million yuan for 2025, a significant improvement compared to the previous year's loss of 175 million yuan [3]. - The company plans to enhance operational efficiency through lean management and cost control measures in its medical sector for 2025 [3]. Group 3 - As of February 6, the stock price of Guangzheng Eye Hospital closed at 4.71 yuan per share, with a total market capitalization of 2.427 billion yuan [4].

中国"1+8+N"战略推进以及海外业务持续双位数增长，共同驱动公司整体收入持续提升。国内业务方 面，公司于2022 年提出新十年"1+8+N"战略，即着力打造1 家世界级眼科医学中心（长沙爱尔）、8 家 国家及区域眼科医学中心（北京、上海、广州、深圳、成都、重庆、武汉、沈阳）、N 家省域一流和地 区领先的眼科医院。截至1H25末，公司境内医院355 家，门诊部240 家。展望未来，随着"1+8+N"战略 的推进和落地，我们相信重点医院辐射作用有望持续加强，门店布局有望完善丰富，带动集团中国收入 持续增长。海外业务方面，公司海外收入于2020-2024 年间实现17.6% CAGR，1H25 实现16.5%YoY 增 速，主要受欧洲子公司Clínica Baviera 和东南亚子公司ISEC 收入增长驱动。展望未来，国际市场空间潜 力巨大，随着公司现有海外业务收入的进一步提升以及未来潜在的海外并购落地，我们认为国际化收入 可在中长期助推公司收入增长。 首次覆盖给予"买入"评级及医疗服务行业首选推荐，目标价人民币14.0 元。我们预计公司于 2025E/2026E/2027E 实现228/250/273亿元收入， ...

Group 1 - The "Optimizing Consumption Environment and Trustworthy Consumption Brand Evaluation Standard" (T/CMBN 0002—2025) was officially launched at the 2025 Brand Strong Country Economic Forum in Beijing, marking a new phase in the systematic and standardized construction of a "trustworthy consumption" environment in China [1][3] - The standard aims to enhance the consumption environment and is part of a broader policy initiative that includes the "Special Action Plan to Boost Consumption" and the "Three-Year Action Plan to Optimize the Consumption Environment," which collectively aim to build a comprehensive consumer confidence protection system [3][4] - The standard includes a complete evaluation index system covering various dimensions such as operational basics, consumer environment creation, quality safety, consumer rights protection, service guarantees, credit integrity, social responsibility, and exclusion criteria, providing scientific guidance for industry standardization and the construction of trustworthy consumption brands [3][4] Group 2 - Aier Eye Hospital Group, as one of the standard drafting units, integrates its development experience to contribute to the optimization of the consumption environment and the construction of a trustworthy consumption ecosystem [3][4] - Aier Eye Hospital has developed a tiered chain model to address the uneven distribution of medical resources, creating a comprehensive eye care service network that promotes the sharing of high-quality medical resources [4][5] - The company has achieved significant growth in outpatient volume, surgical volume, and discharge numbers, with a notably low postoperative infection rate of 0.0156% for high-level surgeries, outperforming international averages [5][6] Group 3 - Aier Eye Hospital is advancing its internationalization efforts and aims to synchronize medical technology, equipment, and pharmaceuticals with international standards, ensuring that innovative technologies benefit Chinese eye care patients sooner [5][6] - The company is enhancing its medical service precision, accessibility, and efficiency through digital transformation, introducing a "Digital Eye Care" model that leverages AI and other advanced technologies for comprehensive management of eye health services [5][6] - Moving forward, Aier Eye Hospital will use the new standard as a key guideline to deepen technological innovation and upgrade service quality, contributing to the high-quality development of the Chinese ophthalmology industry and the construction of a trustworthy medical consumption ecosystem [6]

Core Viewpoint - He Eye Hospital has confirmed that recent shareholder reduction actions were conducted in compliance with legal regulations and are based on the shareholders' own financial needs, emphasizing respect for shareholders' rights and market choices [1] Group 1: Shareholder Actions - The company stated that shareholders have fulfilled their information disclosure obligations regarding the reduction of shares [1] - The reduction actions are driven by the shareholders' independent financial decisions [1] Group 2: Company Strategy - He Eye Hospital will continue to focus on long-term value creation while enhancing internal operational efficiency and core service capabilities [1] - The company aims to adapt to global technological innovations and economic development trends by exploring and promoting sustainable public health service models in the ophthalmology sector [1] - The commitment to social responsibility and corporate value is highlighted, with a focus on safeguarding the long-term interests of all shareholders [1]

Group 1 - The core viewpoint of the article highlights that the current Chinese ophthalmology medical service market is characterized by "multiple coexistence, local concentration, and long-term concentration towards leading players" [1] - The industry competition is multidimensional and three-dimensional, with the company maintaining a clear understanding and a long-term, steady strategic determination [1] - Ophthalmology medical services exhibit distinct regional characteristics and strong brand dependence, making it difficult for latecomers to gain advantages once a strong reputation is established in a region [1] Group 2 - The company focuses on building core competencies in medical safety and quality, patient service experience, a well-structured talent pipeline, and technological innovation capabilities [1] - The company leverages systematic and scalable advantages to continuously build a global medical network, standardized management systems, a secure supply chain, and an academic and research platform that connects domestic and international efforts [1] - The overall outlook for the Chinese ophthalmology medical service market remains in a phase of continuous development, with significant long-term potential [1] Group 3 - The company aims to create a comprehensive ophthalmology medical service system that covers the entire lifecycle and offers multi-level services, addressing the differentiated needs of various patient groups [1] - The company is committed to the core value of "patient-centered" care, with a global perspective, focusing on in-depth development, strengthening technology leadership, and talent-driven initiatives [1] - The goal is to continuously consolidate and expand competitive advantages, striving to create long-term, sustainable value for patients and shareholders [1]

Group 1 - The company, Aier Eye Hospital Group, focuses on ophthalmology and is committed to keeping up with advancements in interdisciplinary fields [1]

Core Viewpoint - Aier Eye Hospital announced a cash dividend plan for the first half of 2025, distributing 0.8 RMB per 10 shares to all shareholders, totaling 744 million RMB in cash dividends [1] Group 1: Dividend Details - The cash dividend distribution date is set for January 14, 2026, with the ex-dividend date on January 15, 2026 [1] - A total of 31.36 million shares held in the repurchase special securities account will not participate in this dividend distribution [1]

Group 1 - BYD aims to maintain significant R&D and financial investment to consolidate electrification and promote intelligence in the new "15th Five-Year Plan" period [3] - The company plans to integrate global resources for collaborative innovation and accelerate its global industrial layout to build a world-class Chinese brand [3] - BYD's annual sales have achieved a tenfold growth during the "14th Five-Year Plan" period, establishing it as the largest electric vehicle manufacturer globally [3] Group 2 - Oriental Fortune emphasizes the importance of empowering the real economy and serving people's needs in the financial sector during the "15th Five-Year Plan" [5] - The company aims to leverage technology to connect wealth management and financing needs effectively [5] Group 3 - Moore Threads focuses on accelerating the application of domestic GPUs across various industries to support digital transformation [7] - The company has established a complete technology stack based on a unified architecture, achieving a systematic closed loop from hardware to application [7] Group 4 - Muyuan Foods is committed to producing safe and healthy pork products, aiming for high-quality development in the pig farming industry [9] - The company plans to leverage technology to address industry challenges and contribute to the high-quality development of China's pig farming sector [9] Group 5 - Zhongwei Company aims to achieve 50% to 60% market coverage in high-end semiconductor equipment through organic growth and external expansion [12] - The company emphasizes the importance of technological innovation and industry chain collaboration to enhance global competitiveness [12] Group 6 - Huayou Cobalt plans to align its strategy with national planning during the "15th Five-Year Plan" period, focusing on creating customer value and leading industry development [16] - The company aims to become a leading technology enterprise in energy materials globally [16] Group 7 - Aier Eye Hospital integrates clinical services, research innovation, and public health education into a comprehensive eye health ecosystem [18] - The company is committed to advancing AI diagnostics and expanding its eye health service network [18] Group 8 - Tianci Materials focuses on sustainable development principles, enhancing innovation capabilities in lithium-ion battery materials and specialty chemicals [20] - The company aims to embrace a new growth cycle in the lithium and energy storage industry over the next five years [20] Group 9 - JinkoSolar emphasizes technological innovation as the core driver of its development, aiming to enhance the efficiency of photovoltaic applications [22] - The company is focused on integrating advanced technologies with traditional manufacturing to foster new productive forces [22] Group 10 - Jishi Media aims to integrate cultural and technological advancements, focusing on digital transformation and innovation in the media sector [24] - The company plans to enhance its competitiveness by focusing on AI, data elements, and low-altitude economy [24] Group 11 - China National Machinery Industry Corporation aims to transform into a technology-driven engineering company while embedding its development into the national modernization blueprint [26] - The company plans to enhance its efficiency and investment value through capital market engagement and focus on green engineering and digital infrastructure [26]

Core Viewpoint - Aier Eye Hospital announced plans to acquire partial equity in 39 institutions, including Bozhou Aier and Lianyungang Aier, for a total amount of 963 million yuan, funded by the company's own resources [1] Group 1: Acquisition Details - The board meeting is scheduled for December 24, 2025, to review the acquisition proposal [1] - The total transaction amount is 963 million yuan [1] Group 2: Strategic Intent - The company aims to enhance its market share and competitiveness through external mergers and acquisitions [1] - The acquisition is part of the company's strategy to accelerate national network construction and improve its outlet layout [1] - This move is intended to solidify the company's leading position in the ophthalmology medical market [1]